Deformulation & Characterisation

Home > Clinical Services > Formulation Development > Deformulation & Characterisation

Deformulation & characterisation

De-formulation is the analysis of a product where a lab breaks down a material or product to determine the identity and quantity of its components. Sometimes known as “chemical reverse engineering,” this process enables scientists to take a medication and discover the contents of its core and coatings. This is the method necessary to create a generic version of a medication and requires various chemical processes to discover the exact contents of a formula.

Pharmaceutical de-formulation, the reverse engineering of a product’s formulation, is a necessary process to create generic drugs. Even before patent expiration, skilled chemists must perform a detailed analysis to identify, quantify, and characterize the original formula’s active pharmaceutical ingredients (APIs) and its excipients, whether it’s a drug or supplement.

Successful generics companies are the first to market after patent expiration, bringing bioequivalent products to pharmacies as quickly as possible. They achieve this through having solid reverse engineering programs and by utilising outside labs when necessary to help in the process.

Our Other Services

Sterile Manufacturing

Eramol delivers a purpose-built, EU GMP Annex 1–compliant sterile manufacturing service dedicated to Phase I and Phase II clinical trial supply. Our facility is designed for agility, reliability, and regulatory strength by integrating advanced isolator technology, closed-system processing, moist heat terminal sterilisation and a full end-to-end clinical supply chain — ensuring your sterile injectable, cartridges and pre filled syringes reach patients safely, on time and in full regulatory compliance.

Non Sterile Manufacturing

GMP Production of Tablets, Capsules & Oral Liquids for Phase I–III and Commercial Supply Eramol delivers end-to-end non-sterile manufacturing built on a foundation of quality, regulatory expertise, and Qualified Person (QP) leadership. Our Sevenoaks GMP facility, commissioned in November 2021 and operational since August 2022, supports the full product lifecycle—from early-phase clinical development right through to commercial supply.

Labelling Solutions

Our versatile and extensive labelling solutions have been designed to offer flexibility, economy of scale and to meet the demands of last-minute requirements.

Reliable. Proven. Safe. Effective.

Reliable. Proven. Safe. Effective.

Speak With Us

Products on online services or over the Internet. Electronic commerce draws on
technologies such as mobile commerce application

Scroll to Top